Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian Settings

Valentina Perrone, Serena Losi, Veronica Rogai, Silvia Antonelli, Walid Fakhouri, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi and Luca Degli Esposti
Additional contact information
Valentina Perrone: CliCon S.r.l., Health Economics and Outcomes Research, 40141 Bologna, Italy
Serena Losi: Eli Lilly Italy S.p.A., 50019 Sesto Fiorentino, Italy
Veronica Rogai: Eli Lilly Italy S.p.A., 50019 Sesto Fiorentino, Italy
Silvia Antonelli: Eli Lilly Italy S.p.A., 50019 Sesto Fiorentino, Italy
Walid Fakhouri: Eli Lilly and Company Limited, Windlesham GU20 6PH, UK
Massimo Giovannitti: Eli Lilly Italy S.p.A., 00144 Roma, Italy
Elisa Giacomini: CliCon S.r.l., Health Economics and Outcomes Research, 40141 Bologna, Italy
Diego Sangiorgi: CliCon S.r.l., Health Economics and Outcomes Research, 40141 Bologna, Italy
Luca Degli Esposti: CliCon S.r.l., Health Economics and Outcomes Research, 40141 Bologna, Italy

IJERPH, 2021, vol. 18, issue 11, 1-10

Abstract: This study aimed to evaluate the treatment patterns and pharmacoutilization of patients with rheumatoid arthritis (RA) in real-world settings in Italy. This retrospective observational analysis was based on administrative databases of selected Italian entities. All adult patients with RA diagnosis confirmed by ?1 discharge diagnosis of RA (ICD-9-CM code = 714.0) or an active exemption code (006.714.0) were enrolled in 2019. Two cohorts were created: one included patients prescribed baricitinib, the other those prescribed biological disease-modifying antirheumatic drugs (bDMARDs). Overall, 47,711 RA patients were identified, most of them without DMARD prescription. As a first-line prescription, 43.2% of patients were prescribed conventional synthetic DMARDs (csDMARDs), 5.2% bDMARDs and 0.3% baricitinib. In 2019, 82.6% of csDMARD users continued with the same DMARD category, 15.9% had a bDMARD, while 1.5% had baricitinib as second-line therapy. Overall, 445 patients used baricitinib during 2019. During follow-up, baricitinib was prescribed as monotherapy to 31% of patients, as cotreatment with csDMARDs and corticosteroids to 27% of patients, with corticosteroids to 28% of patients and with csDMARDs to 14% of patients. In line with previous findings, a trend of bDMARD undertreatment was observed. The treatment patterns of baricitinib patients could help to better characterize patients eligible for new therapeutic options that will be available in the future.

Keywords: biologic drugs; baricitinib; Janus kinase inhibitors; rheumatoid arthritis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/11/5679/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/11/5679/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:11:p:5679-:d:562239

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().